Propensity-matched analysis to compare the therapeutic efficacies of cefuroxime versus cefotaxime as initial antimicrobial therapy for community-onset complicated nonobstructive acute pyelonephritis due to Enterobacteriaceae infection in women

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 5, 2015, Pages 2488-2495

  Chang, U Im ^a   Kim, Hyung Wook ^a   Wie, Seong Heon ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMPICILLIN; C REACTIVE PROTEIN; CEFOTAXIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

ACUTE PYELONEPHRITIS; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOOD ANALYSIS; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMMUNITY CARE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG TREATMENT FAILURE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NONOBSTRUCTIVE ACUTE PYELONEPHRITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SPECIES IDENTIFICATION; THERAPY EFFECT; TIME TO TREATMENT; TREATMENT DURATION; ACUTE DISEASE; COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION; ENTEROBACTERIACEAE INFECTIONS; MIDDLE AGED; PATHOLOGY; PYELONEPHRITIS; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; ANTI-BACTERIAL AGENTS; CEFOTAXIME; CEFUROXIME; COMMUNITY-ACQUIRED INFECTIONS; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MIDDLE AGED; PYELONEPHRITIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84931292157     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04421-14     Document Type: Article

References (21)

1. Johansen TE, Botto H, Cek M, Grabe M, Tenke P, Wagenlehner FM, Naber KG. 2011. Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system. Int J Antimicrob Agents 38S:64-70. http://dx.doi.org/10.1016/j.ijantimicag.2011.09.009.
2. Bader MS, Hawboldt J, Brooks A. 2010. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med 122:7-15. http://dx.doi.org/10.3810/pgm.2010.11.2217.
3. Takahashi S, Kurimura Y, Takeyama K, Hashimoto K, Miyamoto S, Ichihara K, Igarashi M, Hashimoto J, Furuya R, Hotta H, Uchida K, Miyao N, Yanase M, Takagi Y, Tachiki H, Taguchi K, Tsukamoto T. 2009. Efficacy of treatment with carbapenems and third-generation cephalosporins for patients with febrile complicated pyelonephritis. J Infect Chemother 15:390-395. http://dx.doi.org/10.1007/s10156-009-0721-9.
4. O'Callaghan CH, Sykes RB, Griffiths A, Thornton JE. 1976. Cefuroxime, a new cephalosporin antibiotic: activity in vitro. Antimicrob Agents Chemother 9:511-519. http://dx.doi.org/10.1128/AAC.9.3.511.
5. Jones RN, Fuchs PC, Gavan TL, Gerlach EH, Barry AL, Thornsberry C. 1977. Cefuroxime, a new parenteral cephalosporin: collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolates. Antimicrob Agents Chemother 12:47-50. http://dx.doi.org/10.1128/AAC.12.1.47.
6. Hermanides HS, Hulscher ME, Schouten JA, Prins JM, Geerlings SE. 2008. Development of quality indicators for the antibiotic treatment of complicated urinary tract infections: a first step to measure and improve care. Clin Infect Dis 46:703-711. http://dx.doi.org/10.1086/527384.
7. The Korean Society of Infectious Diseases, The Korean Society for Chemotherapy, Korean Association of Urogenital Tract Infection and Inflammation, The Korean Society of Clinical Microbiology. 2011. Clinical guideline for the diagnosis and treatment of urinary tract infection: asymptomatic bacteriuria, uncomplicated & complicated urinary tract infections, bacterial prostatitis. Infect Chemother 43:1-25. http://dx.doi.org/10.3947/ic.2011.43.1.1.
8. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE, Infectious Diseases Society of America, European Society for Microbiology and Infectious Diseases. 2011. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103-e120. http://dx.doi.org/10.1093/cid/ciq257.
9. Ramakrishnan K, Scheid DC. 2005. Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician 71:933-942.
10. Wi YM, Kim SW, Chang HH, Jung SI, Kim YS, Cheong HS, Ki HK, Son JS, Kwon KT, Heo ST, Yeom JS, Ko KS, Kang CI, Chung DR, Peck KR, Song JH. 2014. Predictors of uropathogens other than Escherichia coli in patients with community-onset acute pyelonephritis. Int J Clin Pract 68: 749-755. http://dx.doi.org/10.1111/ijcp.12368.
11. Wie SH, Kim HW, Chang UI. 2013. Use of gentamicin for women with community-acquired uncomplicated acute pyelonephritis caused by gentamicin-susceptible or -resistant Escherichia coli: 10-year experience. Microb Drug Resist 19:316-322. http://dx.doi.org/10.1089/mdr.2012.0140.
12. Lim SK, Park IW, Lee WG, Kim HK, Choi YH. 2012. Change of antimicrobial susceptibilities among Escherichia coli strains isolated from female patients with community-onset acute pyelonephritis. Yonsei Med J 53:164-171. http://dx.doi.org/10.3349/ymj.2012.53.1.164.
13. Wie SH, Ki M, Kim J, Cho YK, Lim SK, Lee JS, Kwon KT, Lee H, Cheong HJ, Park DW, Ryu SY, Chung MH, Pai H. 2013. Clinical characteristics predicting early clinical failure after 72 h of antibiotic treatment in women with community-onset acute pyelonephritis: a prospective multicenter study. Clin Microbiol Infect 20:O721-O729. http://dx.doi.org/10.1111/1469-0691.12500.
14. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. CLSI document M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
15. York MK. 2007. Aerobic bacteriology, p 3.12.1-3.12.15. In Isenberg HD (ed), Clinical microbiology procedures handbook, 2nd ed. ASM Press, Washington, DC.
16. Nicolle LE. 2011. Update in adult urinary tract infection. Curr Infect Dis Rep 13:552-560. http://dx.doi.org/10.1007/s11908-011-0212-x.
17. Nicolle LE, AMMI Canada Guidelines Committee. 2005. Complicated urinary tract infection in adults. Can J Infect Dis Med Microbiol 16:349-360.
18. Ronald AR, Harding GK. 1997. Complicated urinary tract infections. Infect Dis Clin North Am 11:583-592. http://dx.doi.org/10.1016/S0891-5520(05)70374-3.
19. Pertel PE, Haverstock D. 2006. Risk factors for a poor outcome after therapy for acute pyelonephritis. BJU Int 98:141-147. http://dx.doi.org/10.1111/j.1464-410X.2006.06222.x.
20. Efstathiou SP, Pefanis AV, Tsioulos DI, Zacharos ID, Tsiakou AG, Mitromaras AG, Mastorantonakis SE, Kanavaki SN, Mountokalakis TD. 2003. Acute pyelonephritis in adults: prediction of mortality and failure of treatment. Arch Intern Med 163:1206-1212. http://dx.doi.org/10.1001/archinte.163.10.1206.
21. Naver KG, Savov O, Salmen HC. 2002. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. Int J Antimicrob Agents 19:95-103. http://dx.doi.org/10.1016/S0924-8579(01)00481-2.